Melissano Germano, Civilini Efrem, Maisano Francesco, Castiglioni Alessandro, Asso Bertoglio Luca, Setacci Francesco, Carozzo Andrea, Magrin Silvio, Zangrillo Alberto, La Canna Giovanni, Alfieri Ottavio, Chiesa Roberto
Università Vita-Salute San Raffaele, Milano.
Ital Heart J Suppl. 2004 Sep;5(9):727-34.
Traditional repair of aortic arch aneurysms requires cardiopulmonary bypass, hypothermia and circulatory arrest. Endovascular repair is an attractive, less invasive alternative that may change our therapeutic approach. The aim of this study was to review our clinical experience with endovascular treatment of aortic arch aneurysms and to address the new problems in this area.
In the last 5 years, we treated 21 patients for aortic arch pathology with an "off-pump" endovascular repair (18 men, 3 women, mean age 71.4 +/- 7.2 years). We used 26 stent grafts (5 Gore Excluder TAG, 3 Endomed Endofit, 6 Medtronic Talent, 12 Cook Zenith TX1) with a mean of 1.2 graft/patient. Proximal fixation of endograft was achieved by means of aortic "de-branching" in 11 cases. In 10 cases the left subclavian artery was intentionally covered without revascularization. Follow-up included clinical examination, chest X-ray and computed tomography at discharge and at 6-month intervals thereafter.
Technical success was 85% (18/21). There was one in-hospital death (4.7%) due to endograft migration. We observed 2 cases of type I endoleak (9.5%). One surgical conversion was performed 2 weeks after the procedure, because of total collapse of the stent graft with rupture of three stents. No complications related to the coverage of the left subclavian artery were observed. At a mean follow-up of 18.7 +/- 12.8 months, no mortality or morbidity including new-onset endoleak, stent-graft migration and thrombosis of supra-aortic grafts were recorded.
Endovascular treatment of aortic arch pathology is feasible even in elderly patients. However, accurate placement in the arch and aneurysm sealing with the currently available devices, may be challenging due to the involvement of supra-aortic vessels, the anatomical curvature of the arch, the high blood flow, and substantial movement of the aorta with each heartbeat.
传统的主动脉弓动脉瘤修复需要体外循环、低温和循环停止。血管内修复是一种有吸引力的、侵入性较小的替代方法,可能会改变我们的治疗方法。本研究的目的是回顾我们血管内治疗主动脉弓动脉瘤的临床经验,并探讨该领域的新问题。
在过去5年中,我们采用“非体外循环”血管内修复术治疗了21例主动脉弓病变患者(18例男性,3例女性,平均年龄71.4±7.2岁)。我们使用了26个支架移植物(5个戈尔Excluder TAG、3个Endomed Endofit、6个美敦力Talent、12个库克Zenith TX1),平均每位患者使用1.2个移植物。11例患者通过主动脉“去分支”实现了移植物的近端固定。10例患者故意覆盖左锁骨下动脉而未进行血管重建。随访包括出院时及此后每6个月的临床检查、胸部X线和计算机断层扫描。
技术成功率为85%(18/21)。有1例患者因移植物移位在住院期间死亡(4.7%)。我们观察到2例I型内漏(9.5%)。术后2周进行了1次手术转换,原因是支架移植物完全塌陷,3个支架破裂。未观察到与左锁骨下动脉覆盖相关的并发症。平均随访18.7±12.8个月,未记录到死亡或发病情况,包括新发内漏、支架移植物移位和主动脉弓上移植物血栓形成。
即使是老年患者,血管内治疗主动脉弓病变也是可行的。然而,由于主动脉弓上血管的累及、弓的解剖弯曲、高血流量以及每次心跳时主动脉的大幅移动,使用目前可用的装置在弓内准确放置和封堵动脉瘤可能具有挑战性。